I feel as good as I can be after the ride down from $29+. Bankers just sold about $85 million in stock @$18.50 for additional manufacturing. I freed up some $ to buy more but waiting as I’m outrageously over committed on this one.
Pre-revenue Biotech has been an absolute dumpster fire for several weeks now, along with other speculative plays. There are narratives which make some think twice on buying in HGEN but I think I have some insight on the sustainability of Covid treatments. In pharma, you really want to be first or best, both is golden - and potentially achievable here. Cutting ties with Kite/Gilead just this week is another sign of confidence in my view.
Hgen isn’t going to over-promote their situation, it’s a bad look in general and particularly one with Pharma-bro history. That said, they have BARDA support, so government already in their corner.